NCT00379795View on ClinicalTrials.gov

An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO

NACompletedINTERVENTIONAL

Enrollment

853

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions

Choroidal Neovascularization, Age-related Macular Degeneration

Interventions

DRUG

Ranibizumab 0.5 mg

Ranibizumab intravitreal injection 0.5 mg in a single-dose regimen given on an as needed basis no more frequently than every 30 days (no more than 12 injections per year)